Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

MYPI2025002433A0Undetermined Publication Date: 2020-06-07TILLOTS PHARMA AG
0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002433
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-07
Filing Date
2019-12-06
Publication Date
2020-06-07
Patent Text Reader

Abstract

The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events. No Suitable Fig.
Need to check novelty before this filing date? Find Prior Art